Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J Hamblin

Showing results (261-270 of 264) with videos related to

Pageof 27
Sort By:
You have reached the last page of results.This site can display upto 264 results.
Blood|February 22, 2003
ZAP-70 expression identifies a chronic lymphocytic leukemia subtype with unmutated immunoglobulin genes, inferior clinical outcome, and distinct gene expression profileAdrian Wiestner, Andreas Rosenwald, Todd S Barry, et al.
The Lancet. Respiratory Medicine|May 25, 2019
Long-term treatment with recombinant human pentraxin 2 protein in patients with idiopathic pulmonary fibrosis: an open-label extension studyGanesh Raghu, Bernt van den Blink, Mark J Hamblin, et al.
Neurology|October 15, 2017
Infliximab for the treatment of CNS sarcoidosis: A multi-institutional seriesJeffrey M Gelfand, Michael J Bradshaw, Barney J Stern, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 12, 2012
Alemtuzumab in combination with methylprednisolone is a highly effective induction regimen for patients with chronic lymphocytic leukemia and deletion of TP53: final results of the national cancer research institute CLL206 trialAndrew R Pettitt, Richard Jackson, Stacey Carruthers, et al.
Pageof 27

Showing results (261-270 of 264) with videos related to

Sort By:
Pageof 27
You have reached the last page of results.This site can display upto 264 results.
Blood|February 22, 2003
ZAP-70 expression identifies a chronic lymphocytic leukemia subtype with unmutated immunoglobulin genes, inferior clinical outcome, and distinct gene expression profileAdrian Wiestner, Andreas Rosenwald, Todd S Barry, et al.
The Lancet. Respiratory Medicine|May 25, 2019
Long-term treatment with recombinant human pentraxin 2 protein in patients with idiopathic pulmonary fibrosis: an open-label extension studyGanesh Raghu, Bernt van den Blink, Mark J Hamblin, et al.
Neurology|October 15, 2017
Infliximab for the treatment of CNS sarcoidosis: A multi-institutional seriesJeffrey M Gelfand, Michael J Bradshaw, Barney J Stern, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 12, 2012
Alemtuzumab in combination with methylprednisolone is a highly effective induction regimen for patients with chronic lymphocytic leukemia and deletion of TP53: final results of the national cancer research institute CLL206 trialAndrew R Pettitt, Richard Jackson, Stacey Carruthers, et al.
Pageof 27